Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
YH

Yujiro S. Hata

President and Chief Executive Officer, IDEAYA Biosciences

Appears in 1 story

Notable Quotes

Darovasertib is central to our strategy to save eyes, preserve vision, and extend lives for patients with uveal melanoma, one of the poorest prognosis indications in oncology. — Yujiro Hata, Q1 2026 business update

Stories

IDEAYA Biosciences raises $324 million as lead cancer drug nears FDA filing

Money Moves

Leading the company toward its first FDA filing

IDEAYA Biosciences closed a $323.6 million stock sale on June 10, 2026. The cash lands as the company prepares to file its first drug with the U.S. Food and Drug Administration (FDA).

Updated Yesterday